CTOs on the Move

R1 RCM

www.r1rcm.com

 
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers R1`s proven and scalable operating models seamlessly complement a healthcare organization`s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.r1rcm.com
  • 434 West Ascension Way 6th Floor
    Murray, UT USA 84123
  • Phone: 312.324.7820

Executives

Name Title Contact Details
Sunny Dezendorf
Vice President of Analytics Profile
Neal Vaughan
Director End User Technology & IT Operations Profile
Wesley Eugene
Vice President of Information Technology Strategy and Process Innovation Profile
Bradley Karlin
US-Cyber Security Director Profile
Jay Sreedharan
Chief Technology and Digital Officer Profile

Similar Companies

Reliance Health

Reliance Health is a non-profit community mental health center focused on enhancing health through mental wellness.

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

AMGIT

AMGIT is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WholesomeCo Cannabis

WholesomeCo is a pharmacy in West Bountiful, UT delivering to many areas across the state. Find the best flower, edibles, & more for your cannabis-based treatment.

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.